IL24 and carcinoma: Based on profound and selective antitumor activity in vitro and in animal models, a replication incompetent type 5 Ads expressing MDA-7/IL-24 (Ad.5-mda-7; INGN-241) was tested in a Phase I clinical trial in patients with advanced cancers, including melanomas and carcinomas [17,21,65,151,152,153,154,155,156].